Aprea Therapeutics (NASDAQ:APRE) Given “Outperform” Rating at Wedbush

Wedbush restated their outperform rating on shares of Aprea Therapeutics (NASDAQ:APRE) in a research note issued to investors on Thursday morning,RTT News reports. The brokerage currently has a $11.00 target price on the stock.

Aprea Therapeutics Price Performance

APRE opened at $1.75 on Thursday. The company has a market capitalization of $9.69 million, a price-to-earnings ratio of -0.74 and a beta of 1.22. The business’s 50-day moving average price is $1.72 and its two-hundred day moving average price is $2.52. Aprea Therapeutics has a 1 year low of $1.41 and a 1 year high of $5.01.

Aprea Therapeutics (NASDAQ:APRE) last announced its earnings results on Wednesday, May 14th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.01). The firm had revenue of $0.16 million during the quarter. Aprea Therapeutics had a negative net margin of 1,095.02% and a negative return on equity of 68.39%. Sell-side analysts anticipate that Aprea Therapeutics will post -2.55 earnings per share for the current fiscal year.

Institutional Trading of Aprea Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in APRE. Stonepine Capital Management LLC grew its position in Aprea Therapeutics by 8.8% in the fourth quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company’s stock valued at $491,000 after purchasing an additional 12,047 shares in the last quarter. Landscape Capital Management L.L.C. bought a new stake in Aprea Therapeutics during the 4th quarter worth about $116,000. LPL Financial LLC acquired a new position in shares of Aprea Therapeutics during the 4th quarter worth about $53,000. Finally, BNP Paribas Financial Markets acquired a new position in shares of Aprea Therapeutics during the 4th quarter worth about $43,000. 34.19% of the stock is currently owned by institutional investors and hedge funds.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.